Adam Crystal, President, R&D, on September 01, 2026, sold 27,000 shares in Tango Therapeutics (TNGX) for $603,909. Following the Form 4 filing with the SEC, Crystal has control over a total of 115,743 common shares of the company, with 115,743 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1819133/000119312526381853/xslF345X05/ownership.xml